COAG Stock Forecast: Hemab Therapeutics Holdings, Inc. Price Predictions for 2026-2027
The 5 Wall Street analysts covering Hemab Therapeutics Holdings, Inc. hold a median 12-month price target of $50 — +11.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 1 of 100 as at 1 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
COAG stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Hemab Therapeutics Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (35): Smaller than most of the companies we track.
Issuance (0): The company has been issuing shares or taking on financing, diluting existing holders.
The rank is the raw material. Whether the rules would actually own Hemab Therapeutics Holdings, Inc. — and when they’d sell — is the membership.
COAG stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on COAG, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +11.1% from it.
Of the 9 most recent actions, 3 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 July 2026 | HC Wainwright & Co. | Maintains | Buy | $40 → $52 |
| 13 July 2026 | Jefferies | Maintains | Buy | $39 → $47 |
| 13 July 2026 | Wedbush | Maintains | Outperform | $42 → $55 |
| 26 June 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 17 June 2026 | HC Wainwright & Co. | Initiates | Buy | — |
| 26 May 2026 | Evercore ISI Group | Initiates | Outperform | — |
| 26 May 2026 | Goldman Sachs | Initiates | Buy | — |
| 26 May 2026 | Jefferies | Initiates | Buy | — |
| 26 May 2026 | Wedbush | Initiates | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
COAG analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Hemab Therapeutics Holdings, Inc. (COAG) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −20.4×
- Price / sales
- —
- Price / book
- −10.6×
- EV / EBITDA
- −31.5×
Cheaper than 96% of US stocks
Cheaper than 97% of US stocks
Cheaper than 91% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- 36.2%
- Return on assets
- −32.8%
- Dividend yield
- —
Higher than 90% of US stocks
Higher than 13% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
COAG vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. COAG appears on the weeks it earns a place.
Frequently asked questions about COAG stock
What is the COAG stock price forecast for 2026-2027?
The 5 Wall Street analysts covering Hemab Therapeutics Holdings, Inc. have a median 12-month price target of $50, with estimates ranging from $46 to $55. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is COAG stock a buy right now?
Of the 5 analysts covering Hemab Therapeutics Holdings, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Hemab Therapeutics Holdings, Inc. 1 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank COAG?
As at 1 Aug 2026, Hemab Therapeutics Holdings, Inc. ranks 1 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (35 of 100).
Will COAG stock go up?
No one can know that. What the data says: the median 12-month target from 5 analysts implies +11.1% from the last close, and Ticker Nerd's factor model ranks Hemab Therapeutics Holdings, Inc. 1 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the COAG stock forecast for 2030?
No analyst covering Hemab Therapeutics Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for COAG are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $46 to $55 over the next 12 months.
What does Hemab Therapeutics Holdings, Inc. do?
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company focused on developing antibody-based therapies for rare bleeding and thrombotic disorders.
About Hemab Therapeutics Holdings, Inc.
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company focused on developing antibody-based therapies for rare bleeding and thrombotic disorders. The company pioneers preventative treatments and functional cures targeting conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and Von Willebrand Disease, where current options often fall short in providing effective prophylaxis or long-term management. Hemab's targeted therapies leverage advances in biology and drug modalities to address blood coagulation challenges, aiming to reduce lifelong disease burdens for patients. Operating within the pharmaceuticals and biotech sector, it builds a franchise around select coagulation disorders by uniting expertise in clotting science, patient care, and drug development. Founded in 2020 and headquartered in Cambridge, Massachusetts, Hemab Therapeutics Holdings, Inc. plays a key role in advancing novel solutions for underserved areas of hematology, contributing to improved disease management in rare bleeding disorders.
CEO Dr. Benny Sorensen M.D., Ph.D. · 59 employees · United States · https://www.hemab.com